These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38377526)
1. High Probability of Gene-Drug Interactions Associated with Medication Side Effects in Adolescent Depression: Results from a Randomized Controlled Trial of Pharmacogenetic Testing. Nooraeen S; Croarkin PE; Geske JR; Shekunov J; Orth SS; Romanowicz M; Frye MA; Vande Voort JL J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):28-33. PubMed ID: 38377526 [No Abstract] [Full Text] [Related]
2. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression. Vande Voort JL; Orth SS; Shekunov J; Romanowicz M; Geske JR; Ward JA; Leibman NI; Frye MA; Croarkin PE J Am Acad Child Adolesc Psychiatry; 2022 Jan; 61(1):46-55. PubMed ID: 34099307 [TBL] [Abstract][Full Text] [Related]
3. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487 [TBL] [Abstract][Full Text] [Related]
4. Editorial: Beyond Red Light, Green Light: Examining the Role of Pharmacogenomics in Evidence-Based Care in Child and Adolescent Psychiatry. Namerow LB; Ramsey LB; Malik S; Cortese S; Strawn JR J Am Acad Child Adolesc Psychiatry; 2022 Jan; 61(1):29-31. PubMed ID: 34767918 [TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Winner JG; Carhart JM; Altar CA; Allen JD; Dechairo BM Discov Med; 2013 Nov; 16(89):219-27. PubMed ID: 24229738 [TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder. Groessl EJ; Tally SR; Hillery N; Maciel A; Garces JA J Manag Care Spec Pharm; 2018 Aug; 24(8):726-734. PubMed ID: 30058980 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. Pérez V; Salavert A; Espadaler J; Tuson M; Saiz-Ruiz J; Sáez-Navarro C; Bobes J; Baca-García E; Vieta E; Olivares JM; Rodriguez-Jimenez R; Villagrán JM; Gascón J; Cañete-Crespillo J; Solé M; Saiz PA; Ibáñez Á; de Diego-Adeliño J; ; Menchón JM BMC Psychiatry; 2017 Jul; 17(1):250. PubMed ID: 28705252 [TBL] [Abstract][Full Text] [Related]
11. Clinical validation of combinatorial pharmacogenomic testing and single-gene guidelines in predicting psychotropic medication blood levels and clinical outcomes in patients with depression. Rothschild AJ; Parikh SV; Hain D; Law R; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Shelton RC; Macaluso M; Brown K; Lewis D; Gutin A; Jablonski MR; Greden JF Psychiatry Res; 2021 Feb; 296():113649. PubMed ID: 33360967 [TBL] [Abstract][Full Text] [Related]
12. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies. Rosenblat JD; Lee Y; McIntyre RS J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459 [TBL] [Abstract][Full Text] [Related]
19. Contribution of Pharmacogenetic Testing to Modeled Medication Change Recommendations in a Long-Term Care Population with Polypharmacy. Sugarman EA; Cullors A; Centeno J; Taylor D Drugs Aging; 2016 Dec; 33(12):929-936. PubMed ID: 27826798 [TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of Pharmacogenetic Testing and a Clinical Decision Support Tool to Enhance the Identification of Drug Therapy Problems Through Medication Therapy Management in Polypharmacy Patients. Kim K; Magness JW; Nelson R; Baron V; Brixner DI J Manag Care Spec Pharm; 2018 Dec; 24(12):1250-1259. PubMed ID: 30479202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]